olaparib | sciencenewsnet.in

Breaking News

New CWRU study targets suicide risk among LGBTQ+ youth in Cleveland’s child welfare, juvenile justice systems

Architect: Here’s How to Build Homes in Fire-Prone Areas

Study reveals biomarker for high risk of metastasis

BLACK HOLES CAN COOK FOR THEMSELVES, CHANDRA STUDY SHOWS

Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients with Cirrhosis and Obesity

Study Results: Exploring Gastric Cancer Risk Through Oral Microbiomes

Children’s Hospital Los Angeles Adds Transformative Gene Therapy and Expands to 10 Treatments, Becoming the Largest Provider of Pediatric Cell and Gene Therapies on the West Coast

Cancer risk established before birth

For Osteoarthritis Patients, Radiation Can Bring Winter Weather Relief

The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine Selected as a U.S. Site for Neuralink Clinical Trial

28 Jan, 2025

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men with Biochemically Recurrent Prostate Cancer

August 22, 2024 sarah JonasResearch Results

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.

Sylvester Comprehensive Cancer Center Tip Sheet for Feb. 2024

February 20, 2024 sarah JonasFeature

A guitarist begins 2024 on high note after awake brain surgery, Dr. Damian Green named chief of Transplantation & Cellular Therapy, targeting treatment resistance in CLL, expanding the patient pool for immunotherapy, researching potential new treatments for head and neck cancer, and more are included in this month’s tip sheet.